Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ALT-711: Phase IIb

In the double-blind, U.S. Phase IIb SAPPHIRE and SILVER trials, 210 mg/day of ALT-711 failed to reduce systolic hypertension compared to

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE